Literature DB >> 18204920

Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration.

Daniela Galimberti1, Eliana Venturelli, Chiara Fenoglio, Ilaria Guidi, Chiara Villa, Luigi Bergamaschini, Francesca Cortini, Diego Scalabrini, Pierluigi Baron, Carlo Vergani, Nereo Bresolin, Elio Scarpini.   

Abstract

Cerebrospinal fluid (CSF) levels of interleukin (IL)-6, IL-11 and leukaemia inhibitory factor (LIF) were evaluated in 43 patients with Alzheimer's disease (AD) and 24 patients with frontotemporal lobar degeneration (FTLD) as compared with 30 agematched controls (CON), and correlated with clinical and demographic data and with CSF biomarkers amyloid beta (A beta)42, total tau and tau phosphorylated at position 181 (P-tau). CSF IL-11 mean levels were significantly increased in AD and FTLD as compared with CON (6.5 +/- 4.6 and 6.6 +/- 5.1 versus 3.1 +/- 3.3 pg/ml, P = 0.009). IL-6 mean levels did not differ between patients and CON (P > 0.05),whereas LIF levels were not detectable in patients or in CON. In AD patients, a significantly positive correlation between MMSE scores and IL-11 CSF concentration was observed (r = 0.344, P = 0.028). No correlations with CSF A beta 42, total tau and P-tau were found. IL-11, but not IL-6 levels are increased in AD and FTLD, and the highest peaks were observed in patients with a less severe degree of cognitive deterioration, therefore suggesting a role of this cytokine in early phases of neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18204920     DOI: 10.1007/s00415-008-0737-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  33 in total

1.  Mild cognitive impairment: clinical characterization and outcome.

Authors:  R C Petersen; G E Smith; S C Waring; R J Ivnik; E G Tangalos; E Kokmen
Journal:  Arch Neurol       Date:  1999-03

Review 2.  Gp130 and the interleukin-6 family of cytokines.

Authors:  T Taga; T Kishimoto
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

3.  Neuropoietic cytokines and activin A differentially regulate the phenotype of cultured sympathetic neurons.

Authors:  M J Fann; P H Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

4.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

Authors:  D Blum-Degen; T Müller; W Kuhn; M Gerlach; H Przuntek; P Riederer
Journal:  Neurosci Lett       Date:  1995-12-29       Impact factor: 3.046

Review 5.  Interleukin-11.

Authors:  S X Leng; J A Elias
Journal:  Int J Biochem Cell Biol       Date:  1997 Aug-Sep       Impact factor: 5.085

6.  Induction of rat L-phosphoserine phosphatase by amyloid-beta (1-42) is inhibited by interleukin-11.

Authors:  K Heese; Y Nagai; T Sawada
Journal:  Neurosci Lett       Date:  2000-07-07       Impact factor: 3.046

7.  Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications.

Authors:  M Sjögren; S Folkesson; K Blennow; E Tarkowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

8.  Trophic effects of cardiotrophin-1 and interleukin-11 on rat dorsal root ganglion neurons in vitro.

Authors:  M Thier; M Hall; J K Heath; D Pennica; J Weis
Journal:  Brain Res Mol Brain Res       Date:  1999-01-22

9.  Trophic effects of interleukin-4, -7 and -8 on hippocampal neuronal cultures: potential involvement of glial-derived factors.

Authors:  D M Araujo; C W Cotman
Journal:  Brain Res       Date:  1993-01-08       Impact factor: 3.252

Review 10.  Interleukin 11: an overview.

Authors:  Y C Yang
Journal:  Stem Cells       Date:  1993-11       Impact factor: 6.277

View more
  32 in total

1.  Intrathecal levels of IL-6 in Alzheimer's disease.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2010-01       Impact factor: 4.849

Review 2.  Biomarkers of oxidative damage and inflammation in Alzheimer's disease.

Authors:  Douglas Galasko; Thomas J Montine
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

3.  Mendelian and Sporadic FTD: Disease Risk and Avenues from Genetics to Disease Pathways Through In Silico Modelling.

Authors:  Claudia Manzoni; Raffaele Ferrari
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Fluid Biomarkers of Frontotemporal Lobar Degeneration.

Authors:  Emma L van der Ende; John C van Swieten
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.

Authors:  Pamela Sparks Stein; Michelle J Steffen; Charles Smith; Gregory Jicha; Jeffrey L Ebersole; Erin Abner; Dolph Dawson
Journal:  Alzheimers Dement       Date:  2012-05       Impact factor: 21.566

Review 6.  Clinical phenotypes and genetic biomarkers of FTLD.

Authors:  Daniela Galimberti; Elio Scarpini
Journal:  J Neural Transm (Vienna)       Date:  2012-04-19       Impact factor: 3.575

Review 7.  Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship.

Authors:  Brianne Magouirk Bettcher; Joel H Kramer
Journal:  Neurocase       Date:  2012-04-19       Impact factor: 0.881

8.  Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.

Authors:  Wei Tang; Qiong Huang; Yu-You Yao; Yan Wang; Yi-Le Wu; Zheng-Yu Wang
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

9.  Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in Alzheimer disease.

Authors:  Sonia Chalbot; Henrik Zetterberg; Kaj Blennow; Tormod Fladby; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Clin Chem       Date:  2009-10-22       Impact factor: 8.327

10.  Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition.

Authors:  Paramita Chakrabarty; Karen Jansen-West; Amanda Beccard; Carolina Ceballos-Diaz; Yona Levites; Christophe Verbeeck; Abba C Zubair; Dennis Dickson; Todd E Golde; Pritam Das
Journal:  FASEB J       Date:  2009-10-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.